Aclaris Therapeutics Inc (FRA:8AT)
€ 0.9182 -0.0174 (-1.86%) Market Cap: 66.10 Mil Enterprise Value: -42.89 Mil PE Ratio: 0 PB Ratio: 0.51 GF Score: 48/100

Aclaris Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript

Jun 14, 2023 / 11:40PM GMT
Release Date Price: €11.85
Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - VP

Awesome. Well, thanks so much, everyone, for joining us here for the last session of the day, and thanks to the team from Aclaris. Maybe I'll turn it over to you guys to introduce yourself and give us a brief overview of the company.

Douglas J. Manion
Aclaris Therapeutics, Inc. - CEO, President & Director

Great. Let's start with Kevin.

Kevin Balthaser
Aclaris Therapeutics, Inc. - CFO

Yes. Kevin Balthaser, CFO. I've been into Aclaris now for 6 years. The first 5 of that predominantly spent running finance accounting operations for our former CFO, and I took over for him in January.

Joseph Monahan;Douglas J. Manion
Aclaris Therapeutics, Inc. - Chief Scientific Officer;Aclaris Therapeutics, Inc. - CEO, President &amp

And Joe Monahan, CSO of the company. Started with Aclaris in 2017 when they bought the company that I started back in 2010 called Confluence Life Sciences.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot